NDA 211340/S-001

APPROVAL LETTER

Azurity Pharmaceuticals, Inc.
Attention: Michael Beckloff
Chief Development Officer
7300 W. 110th Street
Ste 950
Overland Park, KS 66210

Dear Michael Beckloff:

Please refer to your Supplemental New Drug Application (sNDA) dated and received October 8, 2020, and your amendment, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Katerzia (amlodipine) oral suspension, 1 mg/mL.

We acknowledge receipt of your amendment dated March 16, 2021, which constituted a complete response to our February 8, 2021, action letter.

This Prior Approval supplemental new drug application provides for removal of (b) (4) (b) (4)

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

We remind you that you must comply with reporting requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Elizabeth Eydelman, MPH, Regulatory Business Process Manager, at (301) 796 - 5071.

Sincerely,

{See appended electronic signature page}

Gurpreet Gill-Sangha, PhD
Branch Chief, Branch 3
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure:
Content of Labeling

Gurpreet
Gill Sangha

Digitally signed by Gurpreet Gill Sangha
Date: 9/13/2021 09:58:29AM
GUID: 5135f2ad000117842392c50c36c7f28a